NuEyes
Develops augmented reality smart glasses for surgeons and dentists to enhance visualization.
Website: https://www.nueyes.com/nuloupes
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | NuEyes Technologies Inc. |
| Tagline | Augmented reality smart glasses for surgeons and dentists |
| Headquarters | Newport Beach, California, United States |
| Founded | 2016 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech (surgical and dental visualization) |
| Technology Type | Hardware (AR headset) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed, ~$22.8K disclosed |
Links
PUBLIC
- Website: https://www.nueyes.com
- LinkedIn: https://www.linkedin.com/company/nueyes
- NuLoupes product page: https://www.nueyes.com/nuloupes
- Founder LinkedIn (Mark Greget): https://www.linkedin.com/in/markgreget/
Executive Summary
PUBLIC
NuEyes is a Newport Beach hardware company building NuLoupes, an augmented reality headset that aims to replace the optical loupes worn by surgeons and dentists with a digital, stereoscopic alternative [NuEyes]. The company received FDA Class I 510(k) exemption for NuLoupes in December 2023, a regulatory milestone that materially shortens the path to commercial sale into U.S. clinical settings [SAGES, Dec 2023]. NuEyes was founded in 2016 by Mark Greget, a U.S. Navy veteran who initially launched the company through StartUp Health to address visual impairment with AR/VR before pivoting the platform toward surgical and dental visualization [Patient Worthy, Jun 2019]. The current product offers a dual 3D camera system with five to six inches of depth of field, variable digital magnification, and the ability to recognize objects, live stream procedures, and surface patient data [Forbes, Apr 2023]. Disclosed outside capital is small (roughly $22,800) with named backers including Openner, Arab Angel, and Seed Group, and the founder has publicly described the company as bootstrapped [AR Show Podcast]. Over the next 12 to 18 months the items most worth tracking are the planned late-2025 commercial launch, the conversion of developer-kit clinicians into paying customers, and any disclosed institutional financing that would let NuEyes scale manufacturing against larger AR incumbents such as Vuzix [Whitefield BioMed].
Data Accuracy: GREEN -- Confirmed by SAGES, Yahoo Finance, NS Medical Devices, MassDevice, and the company's own site.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B (clinical hardware) |
| Industry / Vertical | Healthtech, surgical and dental visualization |
| Technology Type | AR hardware with proprietary camera system |
| Geography | North America (HQ California) |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder (Mark Greget) |
| Funding | Seed, ~$22.8K disclosed; bootstrapped per founder |
Company Overview
PUBLIC
NuEyes began life in 2016 as a consumer-facing AR/VR company aimed at people with low vision, and matured into a clinical hardware company over the following seven years. The original product line addressed conditions such as achromatopsia, congenital nystagmus, and macular degeneration, using a head-worn display to magnify and re-render the visual field for users with impaired sight [Patient Worthy, Jun 2019]. The company was incubated through StartUp Health, the New York-based health-innovation platform, which gave it early exposure to clinical advisors [Patient Worthy, Jun 2019].
The pivot that defines the company today is NuLoupes, a digital replacement for the optical loupes that surgeons and dentists have worn for decades. According to founder Mark Greget, the product was developed in response to ergonomic and visualization limits clinicians described to him during the low-vision work [NuEyes]. NuLoupes is engineered for dental and medical procedures and was designed in conjunction with practicing clinicians [NuEyes]. The most consequential corporate milestone arrived on December 15, 2023, when NuEyes announced FDA Class I 510(k) exemption for NuLoupes, clearing the device for commercial use in the United States [Yahoo Finance, Dec 2023] [SAGES, Dec 2023].
The company is headquartered in Newport Beach, California, and remains small. Public statements from Greget describe a bootstrapped operating posture, with limited outside capital and a deliberate, hardware-paced release schedule [AR Show Podcast]. NuEyes has indicated plans to seed the market with developer kits to clinicians and medical-application developers ahead of broader commercial release, with a launch reported for late 2025 [Medical Device Network] [Whitefield BioMed].
Data Accuracy: GREEN -- Confirmed by Yahoo Finance, SAGES, Patient Worthy, and NuEyes corporate communications.
Product and Technology
MIXED
NuLoupes is a head-worn AR system that swaps the fixed-magnification optics of a traditional dental or surgical loupe for a digital pipeline: dual cameras capture the operative field, the system processes the stereo feed in real time, and the clinician sees the result on integrated micro-displays. The company describes live 3D stereoscopic imaging with near-zero latency and submillimeter-accurate depth perception driven by a proprietary, patent-pending camera system [DrBicuspid]. The hardware provides five to six inches of depth of field through a dual 3D camera arrangement and supports high-resolution variable digital magnification, which lets a clinician change zoom without swapping physical loupes [Forbes, Apr 2023] [Access Newswire].
Beyond optics, NuLoupes is positioned as a computing platform on the head. The company describes object recognition, live streaming of procedures, and the ability to surface patient data in the clinician's field of view [Dental Products Report]. That positioning matters because it converts a single-purpose accessory (the loupe) into a programmable surface that third-party software developers can target, which is why NuEyes has signaled an early developer-kit program rather than a single retail SKU [Medical Device Network]. The regulatory posture is the FDA Class I 510(k) exemption granted in December 2023, which allows U.S. commercial sale without a premarket review for the cleared use case [SAGES, Dec 2023].
Two product realities deserve to be flagged for prospective buyers and investors. First, the company is iterating on pre-production units and has been pushing firmware updates to early hardware in the field, which is consistent with a late-stage hardware ramp rather than a finished, mass-produced product [NuEyes Facebook].
Data Accuracy: GREEN -- Confirmed by SAGES, DrBicuspid, Forbes, and NuEyes product pages.
Market Research and Opportunity
PUBLIC
The market that matters here is the intersection of clinical loupes (a century-old optical accessory worn by most surgeons and a large share of dentists) and head-mounted AR computing, a category that has finally cleared the regulatory bar for routine clinical use. Optical loupes are essentially universal in dentistry and high-frequency in surgical specialties such as ENT, ophthalmology, plastics, and vascular. Replacing or augmenting that installed base with a digital device is the core wager.
Readers should treat the addressable opportunity as a function of three observable inputs: the count of practicing dentists and surgeons in core geographies, the unit economics of a digital loupe versus a $800 to $2,500 optical pair, and the attach rate of software (imaging overlays, EHR integration, telementoring) that a digital platform can monetize on top of hardware. The cited evidence supports the qualitative claim that the device addresses a real, daily pain point in operative ergonomics and visualization [NuEyes] [Forbes, Apr 2023], but a quantified market figure from a named research house is not in the captured sources.
Demand drivers worth naming are the FDA clearance itself, which removes a gating risk for U.S. clinical buyers [SAGES, Dec 2023]; the broader maturation of head-mounted display optics and on-device compute, which has made medical AR practical rather than experimental; and the shift in dentistry toward digital workflows (intraoral scanners, CBCT, chairside CAD/CAM) into which a head-worn camera and display can plug. Adjacent and substitute markets include surgical microscopes (a high-priced incumbent in microsurgery), exoscopes, video-based surgical visualization carts, and consumer-grade AR devices repurposed for clinical demos. The regulatory environment is friendlier for a Class I exempt device than for a diagnostic AR overlay, which would face a tougher review path.
| Sizing claim | Value | Source |
|---|---|---|
| FDA Class I 510(k) exemption granted | December 2023 | [SAGES, Dec 2023] |
| Disclosed outside capital | ~$22,800 | [PitchBook] |
| Reported commercial launch window | Late 2025 | [Whitefield BioMed] |
Analyst takeaway: the cited dataset confirms the regulatory and product milestones but does not yet contain an independent dollar figure for the surgical-and-dental AR market. The investment case therefore rests on penetration of a known clinician installed base rather than on a third-party TAM number.
Data Accuracy: YELLOW -- Regulatory and product facts are well sourced; market sizing is not present in the cited research and is acknowledged as such.
Competitive Landscape
MIXED
NuEyes sits in a narrow lane between general-purpose AR headset makers and traditional medical-optics incumbents, and its FDA-cleared, clinician-specific positioning is the basis of its differentiation.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| NuEyes (NuLoupes) | AR loupes purpose-built for dentists and surgeons | Seed; ~$22.8K disclosed, founder-bootstrapped | FDA Class I 510(k) exempt, patent-pending dual-camera system with submillimeter depth | [SAGES, Dec 2023] [DrBicuspid] [AR Show Podcast] |
| Vuzix | General-purpose enterprise smart glasses with medical use cases | Public (NASDAQ: VUZI) | Broad enterprise install base, multiple form factors, established OEM relationships | structured facts; competitor named in dataset |
The segment-by-segment map looks like this. In the incumbent lane sit traditional optical loupe manufacturers and surgical microscope vendors, whose products are trusted, depreciated, and embedded in clinical purchasing patterns; they compete on optical quality and price, not on compute. In the challenger lane sit purpose-built medical AR companies, of which NuEyes is one, defined by FDA clearance and clinician-led design.
NuEyes' defensible edge today rests on three things the cited evidence supports: a Class I 510(k) exemption that a horizontal AR vendor would need to replicate per indication [SAGES, Dec 2023], a patent-pending camera system tuned for the close-working distances of dental and surgical work [DrBicuspid], and a product architecture co-developed with practicing clinicians [NuEyes]. Whether that edge is durable depends on how quickly a better-capitalized hardware vendor can match the clinical specificity. The patent-pending status and the clinician-design lead time are real but perishable advantages.
Where NuEyes is most exposed is capital and distribution. Vuzix is publicly traded with a multi-year head start on enterprise sales channels, and any of the large medical-device distributors could in principle private-label or partner with a horizontal AR vendor to attack the same use case.
The most plausible 18-month scenario: winner if NuEyes converts its developer-kit cohort into a defensible base of clinician advocates and ships its late-2025 commercial launch into a focused dental beachhead, where purchasing decisions are made by individual practices rather than hospital committees. Loser if a larger AR vendor secures its own 510(k) for a competing surgical-visualization indication and pairs it with an existing distributor relationship before NuEyes raises a priced institutional round.
Data Accuracy: YELLOW -- Subject and one named competitor confirmed; broader competitor map is analytical and is labelled as such.
Opportunity
PUBLIC
If NuEyes executes on its post-clearance launch, the size of the prize is to become the default head-worn computing surface in the operatory and the dental chair, replacing a universally worn but functionally static optical accessory.
The headline opportunity. The single largest outcome NuEyes could plausibly achieve is to define the digital loupe category the way intraoral scanners defined chairside imaging in dentistry: a clinician-worn device that starts as a better loupe and ends as a software platform for imaging overlays, EHR cues, telementoring, and procedure capture. The cited evidence makes that outcome reachable rather than aspirational because the regulatory bar (a Class I 510(k) exemption) is already cleared [SAGES, Dec 2023], the device already supports object recognition and live streaming on top of stereoscopic optics [Dental Products Report], and the founder has been publicly engaged with clinician communities through SAGES and StartUp Health channels [SAGES, Dec 2023] [Patient Worthy, Jun 2019]. The category does not require persuading clinicians to wear something new on their head; it requires persuading them that a digital version of what they already wear is better.
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Dental beachhead | NuLoupes wins individual dental practices first, then dental service organizations, before pushing into surgery | Late-2025 commercial launch with developer-kit clinicians acting as references [Whitefield BioMed] | Dentistry has high loupe penetration and decentralized purchasing, so a small team can sell directly without hospital committees |
| Software platform pivot | Hardware becomes a delivery vehicle for third-party clinical apps (imaging, AI overlays, telementoring) | Developer-kit program seeds an app ecosystem [Medical Device Network] | Object recognition, live streaming, and patient-data display are already in the cited feature set [Dental Products Report] |
| Strategic acquisition | A larger medical-optics or AR vendor acquires NuEyes for the FDA clearance, patent-pending camera, and clinician relationships | A competing 510(k) filing or a distributor partnership announcement | Clearance plus a clinician-validated form factor is a faster acquisition than a multi-year internal build [SAGES, Dec 2023] |
What compounding looks like. The flywheel here is clinician-to-clinician credibility plus a platform layer on top of hardware. Each developer-kit clinician who livestreams a procedure with NuLoupes is a distribution event the company does not have to pay for, and each medical-application developer that targets the device increases switching costs for the hardware. Firmware updates already shipping to pre-production units suggest the iteration loop is functioning [NuEyes Facebook]. The unit economics that matter over time are not the first headset sale; they are attach of software, accessories, and replacement cycles into an installed base of clinicians who have integrated the device into daily workflow.
The size of the win. NuEyes does not need to match a horizontal AR vendor's breadth to be valuable; it needs to own one clinical category. If NuEyes captures even a low-single-digit share of practicing U.S. dentists at a hardware-plus-software ARPU comparable to existing chairside digital tools, the resulting recurring revenue base would justify a valuation materially above the disclosed seed (scenario, not a forecast). The constraint between today's $22.8K disclosed capital and that outcome is execution capital and a sales motion the public record does not yet show, which is why the most consequential event over the next year is not a product announcement but a priced institutional round [PitchBook].
Data Accuracy: YELLOW -- Headline opportunity and scenarios are grounded in cited regulatory, product, and competitor facts; valuation framing is explicitly labelled scenario rather than forecast.
Sources
PUBLIC
[NuEyes] NuLoupes: A Cutting-Edge AR Device Built to Solve a REAL Problem and Enhance the Experience | https://www.nueyes.com/nuloupes-a-cutting-edge-ar-device-built-to-solve-a-real-problem-and-enhance-the-experience
[SAGES, Dec 2023] NuLoupes - A SAGES Technology and Value Assessment | https://www.sages.org/publications/tavac/nuloupes/
[NuEyes] NuLoupes product page | https://www.nueyes.com/nuloupes
[Patient Worthy, Jun 2019] NuEyes: Using Virtual Reality to Improve Vision for Achromatopsia, Congenital Nystagmus & Macular Degeneration Patients | https://patientworthy.com/2019/06/07/nueyes-using-virtual-reality-improve-vision-achromatopsia-congenital-nystagmus-macular-degeneration-patients/
[DrBicuspid] FDA OKs NuEyes' augmented reality loupes | https://www.drbicuspid.com/dental-business/industry-updates/product-updates/article/15661060/fda-oks-nueyes-augmented-reality-loupes
[NS Medical Devices] NuEyes secures FDA approval for augmented reality loupes NuLoupes | https://www.nsmedicaldevices.com/company-news/nueyes-secures-fda-approval-for-augmented-reality-loupes-nuloupes/
[Yahoo Finance, Dec 2023] NuLoupes Receives FDA Approval, Setting a New Standard in Dental and Surgical Visualization | https://finance.yahoo.com/news/nuloupes-receives-fda-approval-setting-120000229.html
[MassDevice] NuEyes wins FDA approval for augmented reality surgical visualization tech | https://www.massdevice.com/nueyes-fda-approval-augmented-reality-tech/
[Medical Device Network] NuEyes clearance for augmented reality loupes | https://www.medicaldevice-network.com/news/nueyes-clearance-augmented-reality-loupes/
[LinkedIn] NuEyes Technologies Inc. company page | https://www.linkedin.com/company/nueyes
[LinkedIn] Mark Greget, CEO and Founder, NuEyes | https://www.linkedin.com/in/markgreget/
[Bloomberg] Mark Greget profile | https://www.bloomberg.com/profile/person/25100503
[AR Show Podcast] Mark Greget (NuEyes) on Bootstrapping an AR Hardware Startup and the Path to the Pro 3 Glasses | https://open.spotify.com/episode/0XhKGgBCDtp0GmmYiEkNYY
[PitchBook] NuEyes Company Profile: Valuation & Investors | https://pitchbook.com/profiles/company/172978-93
[Forbes, Apr 2023] Coverage of NuLoupes dual 3D camera system and Chief Product Officer Fraser Bowie | https://www.forbes.com
[NuEyes Facebook] NuLoupes firmware update post | https://www.facebook.com/nueyesusa
Articles about NuEyes
- NuEyes Is Putting an FDA-Cleared AR Headset on the Surgeon's Forehead — With NuLoupes cleared as a Class I exempt device in late 2023, the bootstrapped Newport Beach company is courting dentists and surgeons tired of fixed-focus optical loupes.